(RxWiki News) The US Food and Drug Administration (FDA) has approved a new medication to treat migraines.
This new approval is for Ubrelvy (ubrogepant). The FDA approved it to treat migraines (with or without aura) in adults.
This medication is not approved to prevent migraine headaches.
Migraines are estimated to affect 37 million in the US, according to FDA.
“Ubrelvy represents an important new option for the acute treatment of migraine in adults, as it is the first drug in its class approved for this indication,” said Dr. Billy Dunn, acting director of the FDA’s Office of Neuroscience, in a press release.
Ubrogepant is available in tablet form and can be taken with or without food. Common side effects include nausea, tiredness and dry mouth.
Ubrelvy may interact with other medications, so it’s important to tell your health care provider about all of the medications you take.
The approval of ubrogepant was granted to Allergan USA, Inc.
Speak with your health care provider if you have any questions.
Written by Anyssa Garza, PharmD, BCMAS